Patents by Inventor Ghotas Evindar

Ghotas Evindar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
    Publication number: 20210078988
    Abstract: Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.
    Type: Application
    Filed: June 27, 2018
    Publication date: March 18, 2021
    Inventors: Ghotas EVINDAR, Wieslaw Mieczyslaw KAZMIERSKI, John Franklin MILLER, Vicente SAMANO, Lita SUWANDI, David TEMELKOFF, Yoshiaki WASHIO, Bing XIA
  • Modulators of indoleamine 2,3-dioxygenase
    Patent number: 10906924
    Abstract: Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: February 2, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Martha Alicia De La Rosa, Hongfeng Deng, Ghotas Evindar, Wieslaw Mieczyslaw Kazmierski, John Franklin Miller, Vicente Samano, Yoshiaki Washio, Bing Xia
  • MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
    Publication number: 20200165280
    Abstract: Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.
    Type: Application
    Filed: June 27, 2018
    Publication date: May 28, 2020
    Inventors: Martha Alicia DE LA ROSA, Hongfeng DENG, Ghotas EVINDAR, Wieslaw Mieczyslaw KAZMIERSKI, John Franklin MILLER, Vicente SAMANO, Yoshiaki WASHIO, Bing XIA
  • Compounds for affinity chromatography and for extending the half-life of a therapeutic agent
    Patent number: 9938243
    Abstract: Compounds useful for affinity chromatography as presented, more particularly for use in affinity chromatography to purify serum albumin, especially human serum albumin (HSA) and fusion proteins thereof. Methods for extending the half-life of therapeutic agents are also presented, particularly therapeutic peptide agents and small molecules, such as by conjugation of compounds described herein to the therapeutic peptide or small molecule, which, upon administration, binds to HSA, thereby providing a prolonged release of the therapeutic agent.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: April 10, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Peter Kumpalume, Oliver Schon, Christine Patricia Donahue, Ghotas Evindar, David I. Israel, David Paolella, Letian Kuai, Ninad V. Prabhu
  • COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT
    Publication number: 20170369448
    Abstract: Compounds useful for affinity chromatography as presented, more particularly for use in affinity chromatography to purify serum albumin, especially human serum albumin (HSA) and fusion proteins thereof. Methods for extending the half-life of therapeutic agents are also presented, particularly therapeutic peptide agents and small molecules, such as by conjugation of compounds described herein to the therapeutic peptide or small molecule, which, upon administration, binds to HSA, thereby providing a prolonged release of the therapeutic agent.
    Type: Application
    Filed: September 7, 2017
    Publication date: December 28, 2017
    Inventors: Peter KUMPALUME, Oliver SCHON, Christine Patricia DONAHUE, Ghotas EVINDAR, David I. ISRAEL, David PAOLELLA, Letian KUAI, Ninad V. PRABHU
  • Compounds for affinity chromatography and for extending the half-life of a therapeutic agent
    Patent number: 9809558
    Abstract: Compounds useful for affinity chromatography as presented, more particularly for use in affinity chromatography to purify serum albumin, especially human serum albumin (HSA) and fusion proteins thereof. Methods for extending the half-life of therapeutic agents are also presented, particularly therapeutic peptide agents and small molecules, such as by conjugation of compounds described herein to the therapeutic peptide or small molecule, which upon administration, binds to HSA, thereby providing a prolonged release of the therapeutic agent.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: November 7, 2017
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Peter Kumpalume, Oliver Schon, Christine Patricia Donahue, Ghotas Evindar, David I. Israel, David Paolella, Letian Kuai, Ninad V. Prabhu
  • COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT
    Publication number: 20160221962
    Abstract: Compounds useful for affinity chromatography as presented, more particularly for use in affinity chromatography to purify serum albumin, especially human serum albumin (HSA) and fusion proteins thereof. Methods for extending the half-life of therapeutic agents are also presented, particularly therapeutic peptide agents and small molecules, such as by conjugation of compounds described herein to the therapeutic peptide or small molecule, which, upon administration, binds to HSA, thereby providing a prolonged release of the therapeutic agent.
    Type: Application
    Filed: October 1, 2014
    Publication date: August 4, 2016
    Inventors: Peter KUMPALUME, Oliver SCHON, Christine Patricia DONAHUE, Ghotas EVINDAR, David I. ISRAEL, David PAOLELLA, Letian KUAI, Ninad V. PRABHU
  • THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS
    Publication number: 20160002273
    Abstract: Provided herein are novel substituted thieno[3,2-d]pyrimidine-6-carboxamide sirtuin inhibitors and methods of use thereof. The sirtuin inhibitors may be used for inhibiting a sirtuin-mediated biological process, and, e.g. for treating and/or preventing diseases and disorders including, but not limited to cancer, neurodegenerative disease and inflammation. Also provided herein are pharmaceutical compositions comprising these sirtuin inhibitors and compositions comprising a sirtuin inhibitor in combination with another therapeutic agent.
    Type: Application
    Filed: March 7, 2014
    Publication date: January 7, 2016
    Inventors: Charles A. BLUM, Jeremy S. DISCH, Ghotas EVINDAR, Robert B. PERNI
  • S1P-1 RECEPTOR AGONISTS
    Publication number: 20110039933
    Abstract: The invention provides compounds formula (I), their preparation, and their use as pharmaceutically active immuno-suppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors.
    Type: Application
    Filed: August 7, 2007
    Publication date: February 17, 2011
    Applicant: PRAECIS PHARMACEUTICALS INCORPORATION
    Inventors: Ghotas Evindar, Hongfeng Deng
  • Sphingosine-1-phosphate (SIP) receptor agonists
    Patent number: 7759370
    Abstract: The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or S1P receptors.
    Type: Grant
    Filed: August 1, 2007
    Date of Patent: July 20, 2010
    Assignee: Praecis Pharmaceuticals
    Inventors: Ghotas Evindar, Hongfeng Deng, Sylvie Bernier, Gang Yao, Aaron Coffin, Hongfang Yang
  • AGONISTS OF SPHINGOSINE-1 PHOSPHATE RECEPTOR (SLP)
    Publication number: 20100016260
    Abstract: The invention provides compounds of formula I and formula II, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors.
    Type: Application
    Filed: August 1, 2007
    Publication date: January 21, 2010
    Applicant: PRAECIS PHARMACEUTICALS INCORPORATED
    Inventors: Hongfeng Deng, Ghotas Evindar, Sylvie Bernier, Gang Yao, Aaron Coffin, Hongfang Yang, Raksha A. Acharya
  • CHEMICAL COMPOUNDS
    Publication number: 20100009936
    Abstract: The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immuno-suppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors.
    Type: Application
    Filed: August 1, 2007
    Publication date: January 14, 2010
    Applicant: PRAECIS PHARMACEUTICALS INCORPORATED
    Inventors: Ghotas Evindar, Hongfeng Deng, Sylvie Bernier, Gang Yao, Aaron Coffin, Hongfang Yang
  • AGONISTS OF THE SPHINGOSINE-1 PHOSPHATE RECEPTOR
    Publication number: 20090318389
    Abstract: The invention provides compounds formulae I-III, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors.
    Type: Application
    Filed: August 2, 2007
    Publication date: December 24, 2009
    Applicant: PRAECIS PHARMACEUTICALS INCORPORATED
    Inventors: Ghotas Evindar, Hongfeng Deng
  • Chemical compounds
    Publication number: 20080096938
    Abstract: The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or S1P receptors.
    Type: Application
    Filed: August 1, 2007
    Publication date: April 24, 2008
    Applicant: Praecis Pharmaceuticals Incorporated
    Inventors: Ghotas Evindar, Hongfeng Deng, Sylvie Bernier, Gang Yao, Aaron Coffin, Hongfang Yang
  • Chemical compounds
    Publication number: 20080070866
    Abstract: The invention provides compounds of formula I and formula II, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or S1P receptors.
    Type: Application
    Filed: August 1, 2007
    Publication date: March 20, 2008
    Applicant: Praecis Pharmaceuticals Incorporated
    Inventors: Hongfeng Deng, Ghotas Evindar, Sylvie Bernier, Gang Yao, Aaron Coffin, Hongfang Yang, Raksha Acharya
  • Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity
    Publication number: 20080064662
    Abstract: The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.
    Type: Application
    Filed: May 22, 2007
    Publication date: March 13, 2008
    Applicant: Praecis Pharmaceuticals incorporated
    Inventors: Ashis Saha, Malcolm Kavarana, Ghotas Evindar, Alexander Satz, Barry Morgan
  • Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
    Patent number: 7241812
    Abstract: The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: July 10, 2007
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Ashis K. Saha, Malcolm J. Kavarana, Ghotas Evindar, Alexander L. Satz, Barry Morgan
  • Inhibitors of p38
    Patent number: 7169779
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: January 30, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Francesco Salituro, Guy Bemis, Huai Gao, Ghotas Evindar
  • Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
    Publication number: 20060223866
    Abstract: The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.
    Type: Application
    Filed: February 6, 2006
    Publication date: October 5, 2006
    Applicant: Praecis Pharmaceuticals, Inc.
    Inventors: Ghotas Evindar, Hongfeng Deng, Barry Morgan
  • Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
    Publication number: 20060135786
    Abstract: The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.
    Type: Application
    Filed: August 12, 2005
    Publication date: June 22, 2006
    Applicant: Praecis Phamaceuticals, Inc.
    Inventors: Ashis Saha, Malcolm Kavarana, Ghotas Evindar, Alexander Satz, Barry Morgan